化工社化工社 化学情報印刷レポート · 研究参考用
(2S,3R)-2-アミノ-3-メチル吉草酸
アロイソロイシン · (2S,3R)-2-アミノ-3-メチル吉草酸 · L-アロイソロイシン · L-allo-イソロイシン · (2S,3R)-2-アミノ-3-メチルペンタン酸 · H-ALLO-ILE-OH · L-allo-Ile-OH · allo-l-isoleucine
識別子と物理属性
| CAS No. | 1509-34-8 |
|---|---|
| 分子式 | C6H13NO2 |
| 平均分子量 | 131.17 g/mol |
| 単同位体質量 | 131.09462866 g/mol |
| SMILES | CCC(C)C(N)C(=O)O |
| InChIKey | AGPKZVBTJJNPAG-UHFFFAOYSA-N |
| PubChem CID | 791 |
| ChEBI | CHEBI:38264 |
| EC No. | 221-464-2 |
| DTXSID | DTXSID80901480 |
| 現地名 | (2S,3R)-2-アミノ-3-メチル吉草酸 |
化学・物理的性質
| XLogP | -1.7 |
|---|---|
| 極性表面積 | 63.3 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 3 |
| 重原子数 | 9 |
| 形式電荷 | 0 |
| 複雑度 | 103 |
| 物質分類 | Biological Agents -> Amino Acids and Derivatives |
| 医薬品 | Pharmaceuticals |
| LogP（分配係数） | -1.70 |
| 食品添加物 | FLAVORING AGENT OR ADJUVANT -> FDA Substance added to food |
| 溶解度 | 21.4 mg/mL at 25 °CSoluble in waterInsoluble in etherInsoluble (in ethanol)メタノール（わずかに、加熱）、水（わずかに、超音波処理）28.18g/L(20℃) |
| 沸点 | 225.00 to 226.00 °C. @ 760.00 mm Hg225.8±23.0 °C(Predicted) |
| 融点 | 275 °C~285 °C |
| Physical Description | Glistening solid[Merck Index] White powder[Sigma-Aldrich MSDS]White crystalline powderodourless |
| 密度 | 1.2930 (estimate) |
| 屈折率 | 1.4630 (estimate) |
| 貯蔵条件 | Store at RT. |
| 外観・状態 | 粉 |
| pKa（酸解離定数） | 2.57±0.24(Predicted) |
| 色 | 白い |
| BRN | 1721791 |
| InChI | 1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5+/m1/s1 |
| InChIKey | AGPKZVBTJJNPAG-UHNVWZDZSA-N |
| SMILES | CC[C@@H](C)[C@H](N)C(O)=O |
| CAS データベース | 1509-34-8(CAS DataBase Reference) |
化学的特性
White to off-white powder
安全性と法規制
| 規制情報 | Chemical: DL-Isoleucine |
|---|---|
| その他の安全情報 | IMAP assessments - DL-Isoleucine: Environment tier I assessment |
| 有害性の概要 | Safe when used as a flavoring agent in food[JECFA] May cause irritation[Sigma-Aldrich MSDS] |
| 暴露経路 | Absorbed from the small intestine by a sodium-dependent active-transport process |
| 毒性の概要 | (Applies to Valine, Leucine and Isoleucine) <br/>This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. <br/>The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoAthus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. <br/>There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the dietultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. |
| Signs and Symptoms | Symptoms of hypoglycemia |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |